Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.-Reference-Cited by-同舟云学术

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:7503-7503
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Antonia Scott Joseph¹,Bendell Johanna C.²,Taylor Matthew Hiram³,Calvo Emiliano⁴,Jaeger Dirk⁵,De Braud Filippo G.⁶,Ott Patrick Alexander⁷,Pietanza M. Catherine⁸,Horn Leora⁹,Le Dung T.¹⁰,Morse Michael¹¹,Lopez-Martin Jose A.¹²,Ascierto Paolo Antonio¹³,Christensen Olaf¹⁴,Grosso Joseph¹⁴,Simon Jason S.¹⁴,Lin Chen-Sheng¹⁵,Eder Joseph Paul¹⁶

Affiliation:

1. Moffitt Cancer Center, Tampa, FL

2. Sarah Cannon Research Institute, Nashville, TN

3. Oregon Health and Science University, Portland, OR

4. START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain

5. National Center for Tumor Diseases, University Hospitals Heidelberg, Heidelberg, Germany

6. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

7. Dana-Farber Cancer Institute, Boston, MA

8. Memorial Sloan Kettering Cancer Center, New York, NY

9. Vanderbilt-Ingram Cancer Center, Nashville, TN

10. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

11. Duke University Medical Center, Durham, NC